Changes in lactate dehydrogenase on admission throughout the COVID-19 pandemic and possible impacts on prognostic capability.
Biomark Med
; 2022 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: covidwho-2009812
ABSTRACT
Introduction:
The enzyme lactate dehydrogenase (LDH) is a good marker of general hyperinflammation correlated with mortality for COVID-19, and is therefore used in prognosis tools. In a current COVID-19 clinical randomized trial (CRT), the blood level of LDH was selected as an inclusion criterion. However, LDH decreased during the pandemic; hence, the impact of this decrease on the prognostic value of LDH for mortality was evaluated.Methods:
Data on LDH levels in 843 patients were obtained and analyzed. Relative risk, standard error and receiver operating characteristic curves were calculated for two cutoff values.Results:
Relative risk lost validity and the area under the curve narrowed by trimester during the pandemic.Conclusion:
The progressive decrease in LDH impacted the capacity to predict mortality in COVID-19. More studies are needed to validate this finding and its implications.
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Tipo de estudio:
Estudio experimental
/
Estudio pronóstico
/
Ensayo controlado aleatorizado
Idioma:
Inglés
Asunto de la revista:
Bioquímica
/
Medicina
Año:
2022
Tipo del documento:
Artículo
País de afiliación:
Bmm-2022-0364
Similares
MEDLINE
...
LILACS
LIS